How has been the historical performance of Bafna Pharma.?

Answer:Bafna Pharma has experienced a significant decline in its financial performance over the years, particularly from 2015 onwards. In terms of net sales, the company reported a decrease from 97.67 Cr in March 2015 to just 43.36 Cr in March 2019. Total operating income followed a similar trend, dropping from 138.79 Cr in March 2015 to 43.36 Cr in March 2019. The company's expenditures have also fluctuated, with total expenditure excluding depreciation peaking at 115.33 Cr in March 2015 and then decreasing to 56.70 Cr by March 2019. Operating profit has been negative since March 2016, with the operating profit margin excluding other income reaching -30.78% in March 2019. Profit before tax has consistently been negative since March 2015, culminating in a loss of -17.28 Cr in March 2019. The net profit has also been in the red, with a loss of -18.87 Cr in March 2019 compared to a profit of 6.18 Cr in March 2015. The company's total assets have decreased from 199.83 Cr in March 2015 to 71.31 Cr in March 2020, while total liabilities have also reduced from 199.83 Cr to 71.31 Cr in the same period. Cash flow from operating activities has been negative since March 2016, with a cash outflow of -34.00 Cr in March 2020.

Breakdown:
Bafna Pharma's financial trajectory shows a stark decline in performance, particularly evident in its net sales, which fell from 97.67 Cr in March 2015 to 43.36 Cr in March 2019. This decline in revenue is mirrored by a drop in total operating income from 138.79 Cr in March 2015 to the same 43.36 Cr in March 2019. The company's expenditures peaked at 115.33 Cr in March 2015 but decreased to 56.70 Cr by March 2019, indicating cost-cutting measures amidst declining revenues. Operating profit has been negative since March 2016, with a significant loss of -13.34 Cr reported in March 2019, leading to a negative operating profit margin of -30.78%. The company has faced consistent losses, with profit before tax reaching -17.28 Cr in March 2019 and net profit at -18.87 Cr, down from a profit of 6.18 Cr in March 2015. Total assets have diminished from 199.83 Cr in March 2015 to 71.31 Cr in March 2020, while total liabilities have also decreased, reflecting the company's shrinking financial base. Cash flow from operating activities has remained negative since March 2016, culminating in a cash outflow of -34.00 Cr in March 2020, further highlighting the company's ongoing financial struggles.